Vedanta Biosciences Granted Third U.S. Patent Covering Methods of Treating Infectious and Allergic Diseases with Bacterial Consortia

CAMBRIDGE, Mass.--()--Vedanta Biosciences, pioneering the development of a novel class of therapies designed to modulate pathways of interaction between the human microbiome and the host immune system, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,433,652. The patent broadly covers methods of treating a variety of diseases including infectious and allergic diseases with mixtures of Clostridium live bacterial strains and further expands Vedanta Biosciences’ patent portfolio after the issuances of U.S. 9,415,079 and U.S. 9,421,230 in August and earlier issuances in Japan. The patents are exclusively licensed to Vedanta Biosciences under an agreement with the University of Tokyo and provide coverage through at least 2031.

The patented technology is based on ground-breaking work by Dr. Kenya Honda, a scientific co-founder of Vedanta Biosciences. Dr. Honda’s work shows that compositions of bacterial strains belonging to Clostridium clusters IV and/or XIVa may potentially be used to treat a range of diseases including infectious, allergic and autoimmune diseases.

“This third U.S. issuance further reinforces our patent portfolio around products based on bacterial consortia, and it also provides important protection for several programs in our pipeline,” said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences.

About Vedanta Biosciences

Vedanta Biosciences is pioneering development of a novel class of therapies designed to modulate pathways of interaction between the human microbiome and the host immune system, with clinical trials in certain indications expected to begin in the first half of 2017. Founded by PureTech Health (PureTech Health plc, PRTC.L) and a group of world-renowned experts in immunology and microbiology, Vedanta Biosciences is a leader in the microbiome field with capabilities to discover, develop and manufacture drugs based on live commensal microbes. Leveraging its proprietary technology platform and the expertise of its team of scientific cofounders, Vedanta Biosciences has isolated a vast collection of human-associated bacterial strains and characterized how the immune system recognizes and responds to these microbes. This work has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells and Th17 cells, among others – as well as the characterization of novel molecular mechanisms of microbial-host communication. These advances have been published in leading peer-reviewed journals including Science,Nature (multiple), Cell and Nature Immunology. Vedanta Biosciences has harnessed these biological insights as well as data from clinical translational collaborations to generate a pipeline of programs in development for infectious disease, autoimmune disease, inflammation and immune-oncology. The clinical potential of therapeutic manipulation of the microbiome has been validated by multiple randomized, controlled trials in infectious disease and inflammatory bowel disease.

Vedanta Biosciences’ scientific co-founders have pioneered the fields of innate immunity, Th17 and regulatory T cell biology, and include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale), Dr. Alexander Rudensky (tri-institutional Professor at the Memorial Sloan-Kettering Institute, the Rockefeller University and Cornell University), Dr. Dan Littman (Professor of Molecular Immunology at NYU), Dr. Brett Finlay (Professor at the University of British Columbia) and Dr. Kenya Honda (Professor, School of Medicine, Keio University).

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

PureTech

Allison Mead, +1 617-651-3156
Director, Communications and Investor Relations
amead@puretechhealth.com